Aromatase

Overview

Aromatase (CYP19A1) is the cytochrome P450 enzyme that catalyzes the final and rate-limiting step of estrogen biosynthesis — the conversion of androgens (testosterone, androstenedione) to estrogens (estradiol, estrone). It is expressed in the ovaries, placenta, adipose tissue, brain, bone, and — critically — in endometriotic lesions where local estrogen production drives disease progression.

Aromatase connects the metal-microbiome axis to estrogen-dependent disease through three pathways: metalloestrogen activation, adipose tissue inflammation, and estrobolome modulation.

Metal Connections

Metalloestrogens

cadmium and nickel are classified as metalloestrogens — metals that mimic estrogen by binding estrogen receptors (ERα) and activating estrogen-responsive gene transcription WITHOUT going through aromatase [1]. This creates a paradox for aromatase inhibitor therapy:

  • Aromatase inhibitors (letrozole, anastrozole) block enzymatic estrogen production but cannot block metalloestrogen activation of ER.
  • Environmental cadmium/nickel exposure may therefore undermine aromatase inhibitor efficacy in breast cancer and endometriosis.

Zinc and Aromatase

  • zinc modulates aromatase activity — zinc deficiency is associated with altered androgen/estrogen ratios. Dietary zinc intake inversely associated with endometriosis risk, potentially through aromatase modulation [2].

Microbiome Connection

Estrobolome Circuit

Aromatase produces estrogen → estrogen is conjugated in the liver → conjugated estrogen enters the gut via bile → gut bacterial beta glucuronidase deconjugates it → free estrogen is reabsorbed (estrobolome recirculation). Dysbiosis alters the estrobolome, disrupting this circuit:

  • Increased beta-glucuronidase activity → more estrogen recirculation → estrogen excess → endometriosis/breast cancer risk [3].
  • Decreased beta-glucuronidase activity → less recirculation → estrogen depletion → metabolic syndrome, osteoporosis risk.

Aromatase and the estrobolome are two halves of estrogen homeostasis — one controls production, the other controls recycling. Both must be intact for normal estrogen levels.

Adipose Aromatase and Obesity-Microbiome Axis

In obesity, adipose tissue becomes a major estrogen source via aromatase expression. The gut microbiome drives obesity-related inflammation → adipose expansion → increased aromatase → peripheral estrogen production. This explains:

  • Sex differences in CRC: Higher estrogen from adipose aromatase in obese men may be protective or pathogenic depending on context [4].
  • Postmenopausal breast cancer: Adipose aromatase becomes the primary estrogen source after ovarian cessation; obesity-driven microbiome inflammation amplifies this.

Disease Relevance

Endometriosis

Endometriotic lesions express aberrant aromatase — normally absent in eutopic endometrium but highly expressed in ectopic lesions, creating local estrogen production that feeds lesion growth independent of ovarian estrogen. Combined with dysbiotic estrobolome (excess beta-glucuronidase recirculating additional estrogen), this creates a dual-source estrogen excess that drives disease [5].

Breast Cancer

Aromatase inhibitors are first-line therapy for ER+ postmenopausal breast cancer. The microbiome modulates treatment response through:

  • Estrobolome activity affecting circulating estrogen levels despite aromatase blockade.
  • Metalloestrogen exposure bypassing aromatase inhibition entirely.

Cross-References

References (5)

  1. ★Aquino NB, Sevigny MB, Sabangan J et al. (2012). Role of Cadmium and Nickel in Estrogen Receptor Signaling and Breast Cancer: Metalloestrogens or Not?. Journal of Environmental Science and Health Part C - Environmental Carcinogenesis and Ecotoxicology Reviews. doi:10.1080/10590501.2012.705159
  2. Huang Y, Wei Y, Liang F et al. (2024). Exploring the link between dietary zinc intake and endometriosis risk: insights from a cross-sectional analysis of American women. BMC Public Health. doi:10.1186/s12889-024-20433-9
  3. Kanakaraju Kaliannan, Ruairi C. Robertson, Kiera Murphy et al. (2018). Kaliannan et al. 2018 — Estrogen-Mediated Gut Microbiome Alterations Influence Sexual Dimorphism in Metabolic Syndrome in Mice. Microbiome. doi:10.1186/s40168-018-0587-0
  4. Zihong Wu, Yuqing Huang, Renyi Zhang et al. (2024). Sex differences in colorectal cancer: with a focus on sex hormone-gut microbiome axis. Cell Communication and Signaling. doi:10.1186/s12964-024-01549-2
  5. Piecuch M, Garbicz J, Waliczek M et al. (2022). I Am the 1 in 10 -- What Should I Eat? A Research Review of Nutrition in Endometriosis. Nutrients. doi:10.3390/nu14245283

Related Articles